RNAC selectabio.com: Enterprise Value to EBITDA Ratio

selectabio.com (RNAC) - corporate logo

Cartesian Therapeutics (RNAC) is implementing robotic systems and AI control to automate the production of RNA-based drugs. The EV/EBITDA valuation trend, which currently stands at 0.00, accompanies the company's development of anti-tumor agents. The business relies on external contractors for manufacturing and testing to avoid plant-related capital expenditures. However, the high cost of personalized medicines and a capital shortage create significant risks for R&D.

Selecta Biosciences - RNAC Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/10/2026)

selectabio.com (RNAC) - metric breakdowns and financial figures

- stock price and consensus target price:
Stock Quotes Cartesian Therapeutics Inc|RNAC - Average Forecast Price
- company stock capitalization data:
Market Valuation Selecta Biosciences Inc.|RNAC - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Cartesian Therapeutics|RNAC - Company Net Assets|Market Capitalization to Book Value Ratio selectabio.com|RNAC - Company Assets
- debt and solvency information:
Debt to Equity Cartesian Therapeutics|RNAC - Long-Term Debt to Equity|Short-Term Debt to Equity Cartesian Therapeutics, Inc.|RNAC - Company Debts|Debt to Book Value Selecta Biosciences Inc.|RNAC - Company Long-Term Loans and Borrowings|Company Short-Term Debts Cartesian Therapeutics|Quick Ratio selectabio.com
- financial results and valuation multiples details:
RNAC - Company Net Income|Expected Profit Cartesian Therapeutics|RNAC - Price to Earnings Multiple|Forward P/E Multiple Cartesian Therapeutics|RNAC - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Selecta Biosciences Inc.|RNAC - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Cartesian Therapeutics|RNAC - Earnings per share for the last four quarters|Quarterly EPS earnings growth selectabio.com|RNAC - Earnings per share increase in current year|Earnings growth forecast for next year Cartesian Therapeutics
Summary company analytics:Cartesian Therapeutics Inc (RNAC)
Original product of Cartesian Therapeutics, Inc.

Investors must identify the fundamental drivers of asset resilience through objective financial metrics. This indicator is calculated as the ratio of total enterprise value to earnings before interest, taxes, depreciation, and amortization. The EV/EBITDA trend allows for an assessment of the company's real value, accounting for its debt load. For Cartesian Therapeutics (RNAC), this indicator confirms investment attractiveness amid high confidence in their RNA platform.

Key competitors

Legend Biotech Inc. - Enterprise Value to EBITDA Ratio|Sana Corp (SANA) - Company Value to EBITDA|AUTL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALLO (allogene.com)|CLLS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Caribou Biosciences Inc.|TIL (Instil Bio, Inc) - EV/EBITDA Multiple|Company Value to EBITDA Genenta GNTA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Century Therapeutics (IPSC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization JSPR (jaspertherapeutics.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Senti Biosciences SNTI|Adaptimmune Therapeutics plc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CERO: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TCRT (Alaunos Therapeutics)|ACHL: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple cargo-tx.com CRGX|PSTX (Poseida Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA 2seventy bio Inc. TSVT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Gracell Biotechnologies Ltd (GRCL)